52427-11-9

Upstream product

• 13048-81-2 (E)-3-(4-methoxyphenyl)-2-methylacrylic acid 
• 52750-06-8 ethyl 2-methyl-3-[4-(methoxy)phenyl]propanoate 
• 148149-45-5 α-methyl-β-(p-methoxy-phenyl)-ethyl propionate 
• 105372-24-5 diethyl [(4-methoxyphenyl)methyl](methyl)malonate 
• 52750-05-7 ethyl (E)-3-(4-methoxyphenyl)-2-methylpropenoate 
• 824-94-2 p-methoxybenzyl chloride 
• 609-08-5 Diethyl methylmalonate 
• 79-10-7 acrylic acid 
• 13048-81-2 (Z)-3-(4-methoxyphenyl)-2-methylacrylic acid 
• 5462-06-6 3-(p-methoxyphenyl)-2-methylpropionaldehyde 
• 140-67-0 Estragole 
• 64-18-6 formic acid 
• 123-11-5 4-methoxy-benzaldehyde 
• 52750-05-7 3-(4-methoxy-phenyl)-2-methyl-acrylic acid ethyl ester 

Downstream Products

• 56935-39-8 α-methyl-β-(p-methoxyphenyl)-propionyl chloride 
• 5464-10-8 6-methoxy-2-methylindanone 
• 83-33-0 inden-1-one 
• 1346513-36-7 C₂₃H₂₄O₃ 
• 182116-61-6 4-{3-Carbamoylmethyl-2-methyl-1-[1-phenyl-meth-(E)-ylidene]-1H-inden-5-yloxy}-butyric acid ethyl ester 
• 177362-72-0 2-(3(Z)-benzylidene-6-methoxy-2-methyl-3H-inden-1-yl)acetamide 
• 182116-58-1 2-(3(Z)-benzylidene-6-hydroxy-2-methyl-3H-inden-1-yl)acetamide 

Relevant academic research and scientific papers

A simple method for the synthesis of 2-amino-1(4′-methoxyphenyl)-propane

Synthesis of 2-amino-1-(4′-methoxyphenyl)-propane (II) starting from p-anisaldehyde (1) in 67% overall yield is described. Key reactions involved Horner-Wadswoth-Emmons olefination of 1 to form the ester 2 and Hoffmann degradation of amide 5 to obtain the amine II.

Pd-Catalyzed Regioselective Branched Hydrocarboxylation of Terminal Olefins with Formic Acid

A regioselective Pd-catalyzed hydrocarboxylation of terminal olefins with HCOOH is described. A wide variety of branched carboxylic acids can readily be obtained with high regioselectivities under mild reaction conditions. The reaction is operationally simple and requires no handling of toxic CO. The ligand and LiCl are important factors for reaction reactivity and selectivity.

Carbonylative Transformation of Allylarenes with CO Surrogates: Tunable Synthesis of 4-Arylbutanoic Acids, 2-Arylbutanoic Acids, and 4-Arylbutanals

In this Communication, procedures for the selective synthesis of 4-arylbutanoic acids, 2-arylbutanoic acids, and 4-arylbutanals from the same allylbenzenes have been developed. With formic acid or TFBen as the CO surrogate, reactions proceed selectively and effectively under carbon monoxide gas-free conditions.

INDANE DERIVATIVES FOR MALODOR COUNTERACTION

The present invention relates to the field of malodor counteraction. More particularly, it concerns malodor masking ingredient having an indane moiety (as defined in formula (I)), as well as malodor masking compositions comprising such ingredients.

DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE

The disclosure provides chemical compounds possessing therapeutic and/or protective properties against oxidative damage. Methods of making such therapeutic and/or protective compounds and associated compositions are also provided, as are methods for their use, which include protecting cells from oxidative damage and/or inhibiting production of ROS in a cell or subject, as well as preventing or reducing the extent of tissue damage caused by an ischemic event in a subject at elevated risk of such an event.

COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER

Disclosed are compounds of formulas I and II, in which R, R0, R1-R4, R7-R10, n, X, Y, Y', and E are as described herein, pharmaceutical compositions containing such compounds. The compounds and pharmaceutical compositions are for use in treating or preventing diseases, for example, cancer.

INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF

Disclosed are compounds, for example, compounds of formula I, wherein R, R0, R1-R8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES

Disclosed are compounds, for example, a compound of formula I, wherein R, R0, R1-R8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation

RXRα represents an intriguing and unique target for pharmacologic interventions. We recently showed that Sulindac and a designed analog could bind to RXRα and modulate its biological activity, including inhibition of the interaction of an N-terminally truncated RXRα (tRXRα) with the p85α regulatory subunit of phosphatidylinositol-3-OH kinase (PI3K). Here we report the synthesis, testing and SAR of a series of novel analogs of Sulindac as potential modulators for inhibiting tRXRα-dependent AKT activation. A new compound 30 was identified to have improved biological activity.

A practical and convenient protocol for the synthesis of (E)-α,β-unsaturated acids

α,β-Unsaturated acids are very useful and versatile reagents in organic synthesis. A novel, practical, and convenient catalytic protocol comprising FeCl3·6H2O (0.5 mol %) and H 2O (1 equiv) in CH3NO2 is described for the rapid synthesis of α,β-unsaturated acids with high E-stereoselectivity under both microwave and conventional heating conditions with high TON and TOF values. This powerful approach efficiently demonstrated the utility of biomass derived aldehydes to build chemical agents used as fuel additives. The method proved to be scalable to gram scale synthesis.